HIV theranostic on track for 2000 submission:
This article was originally published in Clinica
Executive Summary
The US FDA has told Canadian pharmacogenomics company Visible Genetics that it need not complete the clinical trial of its Trugene HIV-1 genotyping kit for directing the treatment of HIV infected individuals. However, Toronto-based Visible Genetics will be required to finish its proficiency trial, which is designed to demonstrate Trugene's quality, reliability, accuracy and reproducibility. Data from the proficiency trial, which should be completed by the end of 1999, will be submitted to the FDA in the first half of 2000 as part of its market approval application for the kit.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.
EU Must Crack Down Harder On Fake Medical Devices, Says Innovator
Counterfeit copies of LifeVac Europe’s anti-choking devices have been registered on the EU’s EUDAMED database and continue to be sold on third-party platforms. Medtech Insight asked director of sales and marketing Matthew Banagan how the company deals with fake devices and what the authorities must do.